Kriya Therapeutics has raised $770.5M across 1 funding round, plus 3 undated rounds. The company is valued at $200M.
Kriya Therapeutics has raised more than $600 million across successive Series A, B and C funding rounds, including a $100 million Series B round completed in 2021. The funding has advanced the company's fully integrated platform for designing, developing and manufacturing gene therapies.
1 funding round, the latest highlighted.
Kriya Therapeutics was founded in 2014, United States.
No date is disclosed for this round.
No filing has been made.
1 dated round, newest first.
Premji InvestLEADQQVTLEADDDexcel PharmaLEADFForesite CapitalLEADBBluebird VenturesLEADNNovartisFFMR LLCSSurveyor CapitalLead investors for each round are in the funding timeline.
The closest gene therapy and biotech peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Kriya Therapeutics is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
